Continuing Education

Continuing Education Information


© 2017 Harborside™


  


ARTICLE

Understanding the Role of Targets and Pathways in the Treatment of Chronic Lymphocytic Leukemia

A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Release date: 12/19/2017

Expiration date: 12/18/2018

Estimated time to complete activity: 3.0 hours

Annenberg Center for Health Sciences
at Eisenhower

39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Voice: 760-773-4500
Fax: 760-773-4513
E-mail: contactce@annenberg.net

Journal of the Advanced Practitioner in Oncology
94 North Woodhull Road
Huntington, NY 11743
Voice: 631-692-0800
Fax: 631-692-0805
E-mail: ckiffer@hbside.com

© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

This activity is supported by unrestricted educational grants from Gilead Sciences Inc. and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Faculty

Christopher Arp, PharmD, Levine Cancer Institute—Carolinas HealthCare System, Department of Pharmacy

Kristan Augustin, PharmD, BCOP, Barnes-Jewish Hospital, Department of Pharmacy

Hani M. Babiker, MD, University of Arizona College of Medicine, Translational Genomics Research Institute, and University of Arizona Cancer Center

Andrew Garcia, PharmD, The University of Arizona Cancer Center

Ashley E. Glode, PharmD, BCOP, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences 

Amy Goodrich, MSN, CRNP, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Alyssa Hinchman, PharmD, The University of Arizona Cancer Center

Lindsay Hladnik, PharmD, BCOP, Washington University in Saint Louis School of Medicine, Department of Medicine

Nadia Khan, MD, Fox Chase Cancer Center

Sandra E. Kurtin, PhDc, ANP-C, AOCN®, The University of Arizona Cancer Center 

Ali McBride, PharmD, BCOP, The University of Arizona Cancer Center

Lisa Nodzon, PhD, ARNP, AOCNP®, Department of Malignant Hematology, Moffitt Cancer Center

Javier Pinilla-Ibarz, MD, PhD, Department of Malignant Hematology, Moffitt Cancer Center

Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Fox Chase Cancer Center

Nina Wagner-Johnston, MD, Johns Hopkins School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Activity Rationale and Purpose

Chronic lymphocytic leukemia (CLL), characterized by uncontrolled proliferation of malignant B lymphocytes, is the most common leukemia in Western countries. With a  population primarily over 70 years of age, frailty and comorbidities are common concerns with established chemoimmunotherapy. Since 2014, new therapies have been approved by the FDA, leading to specialized, specific treatments for the different stages of CLL. This education will review these novel therapies and describe the need for proper diagnostic procedures prior to treatment initiation and monitoring.

Intended Audience

The activity’s target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Learning Objectives

After completing this educational activity, participants should be able to:

  1. Discuss the prominent pathways and targets for novel agents used to treat CLL, including monoclonal antibodies, immunotherapies, small-molecule inhibitors, and immunomodulatory agents.
  2. Apply updated clinical practice guidelines on dosing and response monitoring.
  3. Apply strategies for the prevention and management of adverse events associated with novel therapies used in the treatment of patients with CLL.

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.

ACCME Grayscale

Physicians. The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®).

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider
of continuing nursing education by the American Nurses Credentialing Center’s Commission
on Accreditation. 

A maximum of 3.0 contact hours may be earned for successful completion of this activity. 

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 3.0 contact hours.

CE Pharmacists Logo

Pharmacists. This knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower. 

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-122-H01-P. This program is designated for up to 3.0 contact hours (0.3 CEU) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity. 

Disclosures

Faculty

Christopher Arp, PharmD, has nothing to disclose. 

Kristan Augustin, PharmD, BCOP, has nothing to disclose. 

Hani M. Babiker, MD, has nothing to disclose. 

Andrew Garcia, PharmD, has nothing to disclose. 

Ashley E. Glode, PharmD, BCOP, has nothing to disclose. 

Amy Goodrich, MSN, CRNP, has served on the speakers bureau for Gilead.

Alyssa Hinchman, PharmD, has nothing to disclose. 

Lindsay Hladnik, PharmD, BCOP, has nothing to disclose. 

Nadia Khan, MD, has served as a consultant for AbbVie and has served on the speakers bureau for Genentech.

Sandra E. Kurtin, PhDc, ANP-C, AOCN®, has served as a consultant for AbbVie, Celgene, Genentech, and Pharmacyclics. 

Ali McBride, PharmD, BCOP, has served on speakers bureaus for AbbVie and Incyte.

Lisa Nodzon, PhD, ARNP, AOCNP®, has served as a consultant for Ariad and Gilead; has served on speakers bureaus for Ariad, Bristol-Myers Squibb, Genentech, Gilead, Novartis, and Pfizer; and has received payment for the development of educational presentations for Genentech/AbbVie. 

Javier Pinilla-Ibarz, MD, PhD, has received consulting fees or honoraria from AbbVie, Gilead, Janssen, Pharmacyclics, and Roche.

Barbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, has served as a consultant for AstraZeneca, Bristol-Myers Squibb, Janssen, Jazz Pharmaceuticals, Seattle Genetics, and Takeda/Millennium; and has served on speakers bureaus for Seattle Genetics, Takeda/Millennium, and Teva.

Nina Wagner-Johnston, MD, has nothing to disclose.

ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER

John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc; Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Lead Nurse Planner

Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

Planners

Jeannine Coronna has nothing to disclose.

Claudine Kiffer has nothing to disclose.

A. Kate MacDougall has nothing to disclose. 

Patricia McLafferty has nothing to disclose.

Lynn Rubin has nothing to disclose. 

Annie Yueh has nothing to disclose.

Content Reviewer

Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

To access the learning assessment and evaluation form online,
visit http://surveys.edmeasures.com/s3/PTP-CLL

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.

Save


Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.